PDS Biotech reports updated VERSATILE-002 trial data: mOS 30 months, ORR 36%

PDS Biotechnology Corp

Median overall survival 30 months vs published 12-18 months for pembrolizumab alone.
Objective response rate 36% (19/53); disease control rate 77% (41/53).
21% of patients (11/53) had 90-100% tumor shrinkage; 9% (5/53) complete response.
Phase 3 VERSATILE-003 trial comparing combo vs pembrolizumab monotherapy planned to start in 2024.
Treatment well tolerated; Grade ≥3 AEs in 9 patients (Grade 3 n=8, Grade 4 n=1).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.